NCT04364893View on ClinicalTrials.gov

Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19

NAUnknownINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

April 9, 2020

Primary Completion Date

October 1, 2020

Study Completion Date

December 1, 2020

Conditions
Corona Virus InfectionCOVID-19
Interventions
OTHER

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors

Trial Locations (1)

Unknown

RECRUITING

Idor, São Paulo

Sponsors
All Listed Sponsors
collaborator

Brazilian Clinical Research Institute

OTHER

lead

D'Or Institute for Research and Education

OTHER

NCT04364893 - Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19 | Biotech Hunter | Biotech Hunter